相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Identifying transposable element expression dynamics and heterogeneity during development at the single-cell level with a processing pipeline scTE
Jiangping He et al.
NATURE COMMUNICATIONS (2021)
Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures
Nikita Kotlov et al.
CANCER DISCOVERY (2021)
Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma
Masahiro Yoshida et al.
SCIENTIFIC REPORTS (2021)
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
A. H. Wei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP
Patrizia Mondello et al.
HEMATOLOGICAL ONCOLOGY (2019)
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303
Nancy L. Bartlett et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
Andrew Davies et al.
LANCET ONCOLOGY (2019)
ROBUST: First report of phase III randomized study of lenalidomide/R-CHOP (R2 -CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
U. Vitolo et al.
HEMATOLOGICAL ONCOLOGY (2019)
Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma
Anna Stelling et al.
BLOOD ADVANCES (2019)
Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies
Michael R. Savona et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials
M. J. Maurer et al.
ANNALS OF ONCOLOGY (2018)
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
Naval Daver et al.
LEUKEMIA (2018)
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
John P. Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
Umberto Vitolo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase I study of anti-PD1 in combination with low-dose decitabine in patients with advanced and untreated malignancies.
Chunmeng Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes
G. Garcia-Manero et al.
LEUKEMIA (2016)
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma
Michael Crump et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Diffuse large B-cell lymphoma: R-CHOP failure-what to do?
Bertrand Coiffier et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies
Eric Laille et al.
PLOS ONE (2015)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012
Michel Meignan et al.
LEUKEMIA & LYMPHOMA (2014)
Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration
Xiao-Qian Liu et al.
LEUKEMIA & LYMPHOMA (2014)
Epigenetic Reprogramming of the Type III Interferon Response Potentiates Antiviral Activity and Suppresses Tumor Growth
Siyuan Ding et al.
PLOS BIOLOGY (2014)
An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax
Emmanuel Itti et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial
Richard Delarue et al.
LANCET ONCOLOGY (2013)
Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma
Thomas Clozel et al.
CANCER DISCOVERY (2013)
Alterations of immune response of non-small cell lung cancer with Azacytidine
John Wrangle et al.
ONCOTARGET (2013)
Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP
Leandro Cerchietti et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)
Norbert Schmitz et al.
LANCET ONCOLOGY (2012)
Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab
Kritika Chaiwatanatorn et al.
LEUKEMIA & LYMPHOMA (2009)
Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14)
M Adde et al.
MEDICAL ONCOLOGY (2006)
分享论文
